Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Ionis Pharmaceuticals

Stocks Flashing Renewed Technical Strength: Ionis Pharmaceuticals

Ionis Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

Investors Business Daily

Ionis Pharma's Investigational Drug Shows Promise For Triglyceride And Pancreatitis Reduction

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) on Tuesday released topline results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen for severe hypertriglyceridemia (sHTG).

Benzinga

Ionis Pharma Hits Four-Year High On A 'Home Run' In Triglycerides Treatment

Ionis Pharmaceuticals scored a "home run" Tuesday after its experimental treatment for high triglycerides beat the placebo.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Stocks Flashing Renewed Technical Strength: Ionis Pharmaceuticals

Ionis Pharmaceuticals sees its Relative Strength Rating move into the 80-plus level.

Investors Business Daily

Ionis Pharmaceuticals Reaches 80-Plus Relative Strength Rating Benchmark

Ionis Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81.

Investors Business Daily

Stocks Showing Improving Market Leadership: Ionis Pharmaceuticals Earns 84 RS Rating

A Relative Strength Rating upgrade for Ionis Pharmaceuticals shows improving technical performance.

Investors Business Daily

Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong

Ionis Pharmaceuticals stock surged Monday after the company unveiled promising results for a drug that treats a rare genetic condition.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Ionis Pharmaceuticals Stock Sees IBD RS Rating Climb To 79

Ionis Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Ionis Pharmaceuticals Nosedives After AstraZeneca Drops High Cholesterol Drug Test

Ionis stock tumbled Friday after partner AstraZeneca decided against sending their high cholesterol treatment into Phase 3 testing.

Investors Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022

Upgrades

Benzinga

Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Pfizer’s (NYSE:PFE) lead drug GBS6 or PF-06760805 for the prevention of invasive GBS disease due to the vaccine serotypes in newborns and young infants by active immunization of their mothers during pregnancy. Pfizer shares traded in a…

Benzinga

Ionis Sacrifices A Breakout; Quarterly Miss Outweighs Intact Guide

Ionis Pharmaceuticals kept its 2022 outlook intact Tuesday despite a broad second-quarter miss. But IONS stock tumbled.

Investors Business Daily

Ionis Pharmaceuticals Stock Composite Rating Jumps To 96

The IBD SmartSelect Composite Rating for Ionis Pharmaceuticals increased from 94 to 96 Friday.

Investors Business Daily

Recap of Wednesday's Biotech Catalysts - End of The Day Summary

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Ionis Pharmaceuticals Earnings Perspective: Return On Capital Employed

Benzinga Pro data, Ionis Pharmaceuticals (NASDAQ:IONS) reported Q1 sales of $142.00 million. Earnings fell to a loss of $65.17 million, resulting in a 129.01% decrease from last quarter.

Benzinga

What 5 Analyst Ratings Have To Say About Ionis Pharmaceuticals

Within the last quarter, Ionis Pharmaceuticals (NASDAQ:IONS) has observed the following analyst ratings:

Benzinga

Recap: Ionis Pharmaceuticals Q1 Earnings

Ionis Pharmaceuticals (NASDAQ:IONS) reported its Q1 earnings results on Wednesday, May 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Benzinga

Expert Ratings For Ionis Pharmaceuticals

Within the last quarter, Ionis Pharmaceuticals (NASDAQ:IONS) has observed the following analyst ratings:

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022

Upgrades

Benzinga

What 5 Analyst Ratings Have To Say About Ionis Pharmaceuticals

Ionis Pharmaceuticals (NASDAQ:IONS) has observed the following analyst ratings within the last quarter:

Benzinga

BofA Downgrades Ionis After Vupanorsen Setback: Are There Upcoming Catalysts That Can Help The Stock?

Ionis Pharmaceuticals Inc (NASDAQ: IONS) announced on Monday the discontinuation of the Vupanorsen clinical development program. Following this, there are no high-impact catalysts for the next 12 months that could unlock value, according to BofA Securities.

Investors Business Daily

Pfizer Backs Out Of Deal, But Former Partner Ionis Pares Its Losses

Pfizer backed out of a deal to co-develop an Ionis Pharmaceuticals heart-disease drug on Monday. But IONS stock pared its losses.

Organisations

Investor Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.